TGFB1 and pulmonary fibrosis: The PPAR-γ agonist rosiglitazone attenuates PQ-induced pulmonary fibrosis by upregulating PTEN and decreasing the expression of TGF-β1 in a PPAR-γ-dependent manner [104].